Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.

A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and (ARBs in patients with COVID-19, which all three showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

Cumulative incidences of diagnosed and symptomatic VTE are increased in COVID-19 patients hospitalized in a Dutch hospital, with higher risk in those admitted to the ICU as compared to the general ward.

This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.